Globavir accepted into prestigious Stanford StartX Med Accelerator Program
Globavir Biosciences Inc has recently been accepted into Stanford University's StartX Med Accelerator for the Fall 2014/Winter 2015 cohort. StartX is based in the heart of Silicon Valley and is one of the most prominent and exclusive technology accelerators in the world, historically accepting approximately 8% of Stanford affiliated applicant companies. StartX is now in its fourth year of existence and has lead to 14 successful exits for member companies in the past 18 months.
Through acceptance into this program, Globavir will be able to leverage the following resources to accelerate their growth and milestone achievements over the next several months:
Globavir will be specifically leveraging these resources to launch and sell their PanGlobTM diagnostic assay for detection of Dengue infection and to advance their therapeutics for Ebola and Dengue fever.
Inclusion in the StartX community will accelerate Globavir's near-term growth in measurable and meaningful ways, and represents another important milestone in Globavir's growth as a company.
StartX is a non-profit organization whose mission is to accelerate the development of Stanford's top entrepreneurs through experiential education. StartX benefits from the best mentors in Silicon Valley ranging from entrepreneurs and venture capitalists to industry experts and professors. These mentors provide each company with guidance and advice based on specific needs through calls, lectures, and informal meetings.